Breakthrough medicines are revolutionizing how we fight disease, but when red tape – like prior authorization and step therapy – delay patients’ access to these treatments, patients are unable to realize the full benefits of these medicines. Delays in treatment can lead to higher costs and harmful patient outcomes.

One in three children with epilepsy experienced a delay in starting a new treatment due to prior authorization. 38% of kids who faced a delay missed a dose. 64% of kids who missed doses experienced worsening of seizures.

Patients’ COPD-related Outcomes from Delayed Access to Treatment

When patients with COPD experience delays in treatment, it results in:

- 49% of patients experience an increase in health care costs
- 65% experience worsening symptoms

Delayed treatments for HIV/AIDS are associated with 57 percent poorer health outcomes.

Learn more at PhRMA.org/cost